Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients.
anterior skull base
esthesioneuroblastoma
olfactory neuroblastoma
outcomes
sinonasal malignancy
survival
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
29
03
2022
received:
23
02
2022
accepted:
31
03
2022
pubmed:
7
4
2022
medline:
2
12
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. The goal of this study was to update our oncologic outcomes for this disease and explore prognostic factors associated with survival. We performed a retrospective analysis of patients with ENB treated at a single tertiary care institution from January 1, 1960, to January 1, 2020. Univariate and multivariate analysis was performed. Overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were reported. Among 143 included patients, the 5-year OS was 82.3% and the 5-year PFS was 51.6%; 5-year OS and PFS have improved in the modern era (2005-present). Delayed regional nodal metastasis was the most common site of recurrence in 22% of patients (median, 57 months). On univariate analysis, modified Kadish staging (mKadish) had a negative effect on OS, PFS, and DMFS (p < 0.05). Higher Hyams grade had a negative effect on PFS and DMFS (p < 0.05). Positive margin status had a negative effect on PFS (p < 0.05). Orbital invasion demonstrated worsening OS (hazard ratio, 3.1; p < 0.05). On multivariable analysis, high Hyams grade (3 or 4), high mKadish stage (C+D), and increasing age were independent negative prognostic factors for OS (p < 0.05). High Hyams grade (3+4), high mKadish stage (C+D), age, and positive margin status were independent negative prognostic factors for PFS (p < 0.05). High Hyams grade (3+4) was an independent negative prognostic factor for DMFS (p < 0.05). Patients with low Hyams grade and mKadish stage have favorable 5-year OS, PFS, and DMFS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1457-1467Informations de copyright
© 2022 ARS-AAOA, LLC.
Références
Arnold MA, Farnoosh S, Gore MR. Comparing kadish and modified dulguerov staging systems for olfactory neuroblastoma: an individual participant data meta-analysis. Otolaryngol Head Neck Surg. 2020;163:418-427.
Marinelli JP, Janus JR, Van Gompel JJ, et al. Dural invasion predicts the laterality and development of neck metastases in esthesioneuroblastoma. J Neurol Surg B Skull Base. 2018;79:495-500.
Ow TJ, Bell D, Kupferman ME, Demonte F, Esthesioneuroblastoma HannaEY. Esthesioneuroblastoma. Neurosurg Clin N Am. 2013;24:51-65.
Su SY, Bell D, FerrarottoR, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39:1671-1679.
Miller KC, Marinelli JP, Janus JR, et al. Induction therapy prior to surgical resection for patients presenting with locally advanced esthesioneuroblastoma. J Neurol Surg B Skull Base. 2021;82:e131-e137.
Orton A, Evans D, Boothe D, Lloyd S, Stoddard G, Hitchcock YJ. A proposed revision to the kadish-morita staging system for esthesioneuroblastoma. Int J Radiat Oncol Biol Phys. 2017;98:E30.
Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg. 2009;135:1219-1224.
Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007;133:276-280.
Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012;73:331-336.
Abdou R, Baredes S. Population-based results in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin North Am. 2017;50:481-497.
Low CM, Balakrishnan K, Smith BM, et al. Sinonasal adenocarcinoma: population-based analysis of demographic and socioeconomic disparities. Head Neck. 2021;43:2946-2953.
Mikhael ST, Tadrosse AF, Tadrosse MF, et al. Geographic and socioeconomic factors on survival in esthesioneuroblastoma. Laryngoscope. 2021;131:E2162-E2168.
Chweya CM, Low CM, Van Gompel JJ, Van Abel KM, Stokken JK, Choby G. Population-based analysis on the effect of nodal and distant metastases in sinonasal adenocarcinoma. Head Neck. 2021;43:128-136.
Noone AM, Lund JL, MariottoA, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54:e55-64.
Prevedello DM, Doglietto F, Jane JAJr, Jagannathan J, Han J. History of endoscopic skull base surgery: its evolution and current reality. J Neurosurg. 2007;107:206-213.
Wang EW, Zanation AM, Gardner PA, et al. ICAR: endoscopic skull-base surgery. Int Forum Allergy Rhinol. 2019;9:S145-S365.
Saade RE, Hanna EY, Bell D. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system. Curr Oncol Rep. 2015;17:423.
Tajudeen BA, Arshi A, Suh JD, St John M, Wang MB. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg. 2014;140:1124-1129.
Kane AJ, Sughrue ME, Rutkowski MJ, et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg. 2010;113:340-351.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32:706-714.
Abdelmeguid, AS, et al. Long-term outcomes of olfactory neuroblastoma: md anderson cancer center experience and review of the literature. Laryngoscope. 2022;132(2):290-297.
Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012;73:331-336.
Harvey RJ, Nalavenkata S, SacksR, et al. Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma. Head Neck. 2017;39:2425-2432.
Barinsky GL, Azmy MC, et al. Kilic S. Ann Otol Rhinol Laryngol. 2021;130:136-141.
Zeng Q, Tian Y, HeY, et al. Long-term survival outcomes and treatment experience of 64 patients with esthesioneuroblastoma. Front Oncol. 2021;11:624960.
Song X, Wang J, Wang S, Yan L, Li Y. Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma. Oral Oncol. 2020;103:104618.
Sun M, Wang K, QuY, et al. Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients. Radiat Oncol. 2020;15:219.
Bell D, Saade R, RobertsD, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9:51-59.
Cranmer LD, Chau B, Rockhill JK, Ferreira MJr, Liao JJ. Chemotherapy in esthesioneuroblastoma/olfactory neuroblastoma: an analysis of the surveillance epidemiology and end results (SEER) 1973-2015 database. Am J Clin Oncol. 2020;43:203-209.
Miller KC, Marinelli JP, Van Gompel JJ, et al. Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. Head Neck. 2019;41:1335-1341.
London NRJr, Rooper LM, Bishop JA, et al. Expression of programmed cell death ligand 1 and associated lymphocyte infiltration in olfactory neuroblastoma. World Neurosurg. 2020;135:e187-e193.
Li R, Tian S, Zhu Y, et al. Management of orbital invasion in esthesioneuroblastoma: 14 years' experience. Radiat Oncol. 2019;14:107.
Wang J, Wang L, He H, Li Y, Song X. The treatment outcomes of olfactory neuroblastoma patients with frontal lobe invasion. Front Oncol. 2021;11:640892.